U.S., Feb. 7 -- ClinicalTrials.gov registry received information related to the study (NCT06812546) titled 'Efficacy and Safety of Early Initiation of Vericiguat in Heart Failure After Acute Myocardial Infarction' on Feb. 02.
Brief Summary: Heart failure (HF) is a severe cardiovascular disease with extremely high morbidity and mortality rates worldwide, and ischemic cardiomyopathy is an important cause of heart failure. Vericiguat is a soluble guanylate cyclase stimulator which has been verified to improve the cardiovascular outcomes in heart failure patients. The VICTORIA trial excluded patients with acute coronary syndrome in 3 months prior to the study start, so it is still unclear about the efficacy and safety of vericiguat in heart fa...